Compare iShares MSCI Taiwan ETF (EWT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Novartis AG — how do they compare? iShares MSCI Taiwan ETF trades at $114.1 (market cap $12.74B), while Novartis AG trades at $143.44 (market cap $268.57B). The key difference: Novartis AG is far larger — about 21.1× iShares MSCI Taiwan ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Novartis AG for 82 Days on average.
| EWT | NVS | |
|---|---|---|
Market Cap | $12.74B | $268.57B |
Volume | 8,470,920 | 1,532,573 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $168.62 |
52-Week Low | $60.03 | $121.80 |
Typical Hold Time | 52 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.01, down 1.92% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of its portfolio. Recent news highlights Taiwan's strategic importance in AI chip manufacturing and ongoing US-Taiwan economic cooperation, with Taiwanese companies planning $20 billion in US investments driven by AI demand (Reuters, 2026-09-02).
The outlook remains positive given Taiwan's central role in AI semiconductor supply chains, though geopolitical tensions with China present significant risks. Analyst sentiment is generally bullish with institutional investors increasing positions, including Bank of America's 22.4% stake increase in Q2 2026. Key support levels at $110-$112 provide downside protection while resistance sits at $115-$117.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
